22/06/2026 Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC FDA and EMA accepted cemdisiran regulatory submissions for review for the treatment of gMG Prolium Biosciences announced milestones in systemic sclerosis and refractory lupus nephritis Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC (Ref) Merck announced posi

11/05/2026 Fate Therapeutics showcased FT819 clinical activity in SLE without the use of conditioning chemotherapy at the 2026 ASGCT Annual Meeting Fate Therapeutics showcased FT819 clinical activity in SLE without the use of conditioning chemotherapy at the 2026 ASGCT Annual Meeting (Ref) Fate Therapeutics showcased FT819 (an Off-the-shelf CD19 CAR T-cell therapy) which was being investigated in a Phase 1/ NCT06308978 study in patients with moderate-to-severe systemic lupu

30/03/2026 Aurinia Pharmaceuticals announced acquisition of Kezar Life Sciences Savara announced EMA validation of MAA for MOLBREEVI in autoimmune PAP Aurinia Pharmaceuticals announced acquisition of Kezar Life Sciences ( Ref ) Aurinia Pharmaceuticals entered into a definitive merger agreement to acquire Kezar life sciences for $6.955 per share in cash, plus one non-transferable Contingent Value Right (CVR), which represents the right to receive: Potential payments from the